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Abstract
The European Paediatric Regulation (EUPR) calls for the fostering of high quality ethical research and medicinal 
products to be used in children. The EUPR provides the background, goals, and requirements for paediatric clinical 
trials. Paediatric clinical trials in children are mandatory to generate data on new drugs as well as on drugs used off-
label or for unlicensed indications. The Family Paediatricians Medicines for Children Research Network (FIMP-MCRN) 
was established in 2003 with the aim of developing competence, infrastructure, networking and education for 
paediatric clinical trials. The network, consisting of twenty Paediatric Regional Networks has progressed very well and 
has achieved valuable improvements concerning the conduct of paediatric clinical trials. Furthermore, ad hoc training 
programs have incremented knowledge about clinical trials in Family Paediatrician Investigators (FPI) and have made 
medical professionals as well as the public aware of the need and advantages of trials in children.
Introduction
The main role of children becomes of primary impor-
tance in social organisation and the lack of availability of
medicine for children creates an important problem. This
problem relates to all the children in the world, not only
of developing countries but also from richer parts of the
world [1]. Although many generations of paediatricians
and other physicians have learned to cope with the fact
that off-label or unlicensed medicines are prescribed to
more than half of the children, the time has come to be
sure that medicinal preparations used to treat the paedi-
atric population should undergo a higher quality ethical
research and should be appropriately authorized for use
in the paediatric population [2].
Paediatricians must plan specific clinical trials and
must favour experiments of medicines for children with
higher protection using the right balance between risks
and benefits that are implied in every experiment carried
out on children considering real scientific needs. In com-
parison to adults, metabolic changes during childhood
and adolescence determine fundamental changes which
involve different dosage, administration and elimination
of the medicines which require specific safety and effi-
cacy studies [3].
To improve drug therapy in children and adolescents,
the EUPR publication No 1901/2006 describes the neces-
sity for clinical trials of drugs under development, for
drugs for which changes in dosage forms or new indica-
tions are submitted for approval, and for off-patent drugs
that are unlicensed or used off-label in paediatrics [4,5].
Research and experimentation in Family 
Paediatrics
One of the targets of Family Paediatrics is to carry out
clinical research and experimentations on paediatric
medicines with the ethicality and quality needed to guar-
antee the broadening of knowledge and the improvement
of prescription appropriateness. Authorised drugs should
be used only after having the results of specific studies
which evaluate the effectiveness/safety profile and dosage
for paediatric age groups; pharmacology culture of paedi-
atric age groups needs to be expanded together with the
necessity of offering protection to those children who
participate to clinical trials, avoiding non- necessary
studies, succeeding in gathering evidence about adverse
drug reactions (ADRs) and establishing correct dosage
for each age group [1,3,6].
Research could and must be carried out independently
by Family Paediatricians and some examples have been
set thanks to the specific competence of territorial paedi-
atrics in several areas of excellence. In some cases a "solid
strategic alliance" with other characters that play a key
role in the paediatric research (Universities, Hospitals,
Scientific Institutes for Quality of Healthcare, Scientific
Associations) should be considered and main importance
should be given to a close co-operation and synergy
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between the areas of excellence of national paediatrics
[1,3,7].
Opportunities and challenges for Family 
Paediatrics research
1) Using authorised drugs only after having the results of
specific studies which evaluate the effectiveness/safety
profile and dosage for paediatric age groups; 2) Reducing
"off-label" prescriptions; 3) Sponsoring health and pre-
vention in paediatrics by educating and making family
paediatricians be part of clinical research; 4) Improving
information quality about the use of medicines for chil-
dren; 5) Avoiding non-necessary clinical experimenta-
tions on children and repetition of studies; 6) Offering
protection to children who participate to clinical experi-
mentations; 7) Developing of a pharmacology culture
about paediatric age groups; 8) Determining dosage for
each age group in order to avoid dangerous adverse drug
reactions.
The area of excellence of Family Paediatrics "Research
and Investigations" has been organised by setting up a
research network which has the following targets: 1) a
build up of specific competence; 2) an organisation of the
structure of the research area; 3) an accuracy of method
and quality control of clinical trials. 4) an international
activity by being part of networks of European excellence.
5) a projection towards independent research [1,3,7].
Pharmacological experimentation, phase III and IV
Clinical research, experimentation and practice are all
important aspects of the medical and paediatric profes-
sions and, as for territorial paediatrics, what is well
known is that it has greater possibilities compared to hos-
pitals and universities when safety research has to be car-
ried out especially for some categories of medicines or for
those illnesses which are not followed by hospitalisation,
considering the de-hospitalisation of many pathologies,
especially in paediatric age groups [1,3,7,8].
Today, unfortunately, companies are not very inclined
to carry out clinical studies on medicines of paediatric
use because, except for only some therapeutic categories,
paediatric use represents only a small slice of the market
and therefore many drugs are used inappropriately with
negative safety effects in children. We also know that
some ADRs can be noticed in quality (type of side effect)
and quantity (real incidence in the population treated
with the drug) only after the commercialisation and dur-
ing the use in the "normal" population and not in those
people selected for experimentation. When the drug is
u s e d  i n  c l i n i c a l  p r a c t i c e  w i t h  l a r g e  n u m b e r s  o f  n o n
selected people, post-marketing epidemiological studies
can be useful because of the feedback of all the events
which occur during surveillance, with the estimate of
ADR incidences which cannot be obtained through spon-
taneous report [3,9,10].
Ministerial Decree n. 139/2001
Family Paediatricians can carry out phase three and four
of clinical studies according to the Ministerial Decree
139/2001 which states: 1) Clinical experimentations of
phase III medicines and special phase IV clinical experi-
mentations can be carried out by Community Based Pae-
diatricians (CBP); 2) General practitioners and CBP
authorised to carry out clinical experimentations must be
enrolled in a specific register which is established and
updated by each Local Health Board. CBP, enrolled in
specific Local Health Board registers, are authorised by
the general manager of the local health board to carry out
experimentations after a previous positive opinion of the
Ethics Committee; 3) Public Health develops training
activities which have the aim to improve the competence
of CBP' clinical research, standardise procedures which
lead to qualifications needed for a good clinical practice
and improve Local Health Board inspections; 4) Experi-
mentations can be carried out in all those surgeries, of
both single and/or associate doctors, which have all the
characteristics (logistics, instrumentations, etc.) in accor-
dance with the protocol of studies and the principles of
good clinical practice (ICH-GCP); 5) Experimenters are
not allowed to have direct business relations with their
sponsors; any kind of business relation must be made
with the Local Health Board and the latter must draw up
the measures laid down during the agreement. The
experimenter's pay will be decided by the Local Health
Board within the limits of its medical care plan and it
could preferably consist of the development of infrastruc-
tures, service, equipment and staff; 6) Experimentation
results must be made known and used for the purpose of
submitting an application in case of issue or renewal of
the authorisation for the commercialisation of the medi-
cine.
AIFA Regulation n. 76 of 31/03/2008: observational 
studies
In March 2008, the guidelines for observational studies
were published. The key points of the Decree about
Observational Studies: AIFA guidelines (Official Gazette
n. 76 of 31/03/2008) are as follows: 1) the National regis-
ter of observational studies has been established at AIFA
and all the data referring to these studies should be sent
by computer; 2) it is not necessary that General Medicine
doctors and CBP should be enrolled in the registers
according to the Ministerial Decree DM 139/2001 in
order to carry out observational studies; 3) a formal
request of approval must be made to the Ethics Commit-
tee for prospective cohort studies during which patientsNapoleone and Mele Italian Journal of Pediatrics 2010, 36:46
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are followed and treated pharmacologically for any future
evaluations of the results; 4) for all other types of studies a
notification to the Ethics Committees of the institutes
which participate is necessary and the study can be
started after sixty days from the notification with a tacit
consent.
Therefore, after having cast light on these regulations,
we understand that all Italian Family Paediatricians can
carry out epidemiological observational studies, phase IV
studies, post marketing studies and surveillance studies.
On the other hand, only those paediatricians (FPI) who
are enrolled in the experimenters' registers (established
by Local Health Boards), that is all the paediatricians who
have attended and passed training courses voluntarily
and that have ambulatories with necessary requirements,
can carry out experimental studies.
The Ministerial Decree D.M. 139/2001 avoids any con-
flicts of interest by banning all business relations between
sponsors and FPI as only Local Health Boards can make
economical agreements, suggesting a development of
infrastructures and service as payment.
The FIMP-MRCN
The difficulties when running paediatric trials and the
complexity of their methodological procedures as well as
the lack of know-how when running paediatric trials and
the need of resources, have all led to the decision to cre-
ate the FIMP Medicines for the Children Research Net-
work (FIMP-MCRN).
The FIMP-MCRN founded in April 2003. It has been
created to improve international standards of ethics and
scientific quality by means of an agreement between indi-
viduals co-operating for the same objectives, goals and
quality standards. More than 6000 Italian Family Paedia-
tricians are involved from 20 Italian Regions (every Ital-
ian Region is coordinated by a Regional Referent),
covering the entire Italian territory. Until now about a
thousand of these Family Paediatricians have attended
training courses voluntarily and enrolled in experiment-
ers registers, becoming FPI [8-13]. Since every paediatri-
cian takes care of 900 children and follows them from
their birth to 14 years of age, the FIMP-MCRN can sur-
vey more than 6.000.000 Italian children. Family Paedia-
tricians (FP) are an important reference for those families
with which they establish a strong and long lasting rela-
tionship based on trust [8-13].
The aims of the FIMP-MCRN are: 1) to work with the
international standards of ethics and scientific quality in
order to follow the planning, carrying out, registration
and report of clinical investigations that are involved in
paedia tric subjects (Good Clinical Practice); 2) t o pro-
mote the availability of safe and effective medicines for
children; 3) to identify specific needs for the use of
medicinal products in order to avoid duplicates of the
various investigations in children and to pay attention to
those that are the most biased in clinical studies; 4) to
assess the efficacy of new medicines for children; 5) to
survey the use of off-label and unlicensed children drugs;
6) to use orphan drugs in children; 7) to validate clinical
methods for assessing the safety and efficacy of new med-
icines for children and also of those in use; 8) to survey
adverse drug reactions (ADRs) and to promote the use of
Case Report Forms [8-13].
Because of the elevated number of patients being fol-
lowed, this Network is a great resource for all the investi-
gations carried out on the use of medicines for children.
The FIMP supports paediatric trials thanks to its struc-
ture which includes the FIMP-MCRN, 20 Local Research
Networks, 6 Sub speciality Networks, special FIMP
Working Groups and the National "Research and Investi-
gations" Paediatric School.
The FP-Investigators took part in the majority of the
most important clinical studies carried out in Italy in the
last 6 years, helping in a considerable manner to create
quality research and to acquire a high level of compe-
tence. In this way FIMP-MCRN guarantees continuity in
time and constant cooperation between national and
international networks [8-13].
Six sub-speciality networks have already been set up
(vaccines, nutrition, phytotherapy, allergology, dermatol-
ogy, gastroenterology) each led by a national representa-
tive and supported by other 20 regional representatives.
All groups work "in synergy" with a continuous and con-
stant exchange of information. For the past 6 years, the
members of the FIMP-MCRN have had valuable experi-
ence in networking. It is obvious that networking
requires, besides paediatric and trial excellence, also team
spirit, team players and shared goals as well as natural
trust and confidence.
The FIMP - MCRN have developed and improved
expertise in: observational and epidemiological studies;
long term follow up (LTFU) clinical studies; efficacy stud-
ies (DBPC-RTC and/or comparative treatment studies);
safety studies (Post-marketing, Pharmacovigilance, Phase
4 clinical studies).
FIMP Training Program
Family paediatricians interested in drug research and
investigation must attend voluntarily specific training
courses which are organized in all Italian regions and/or
districts as established by the Ministerial Decree D.M.
139/2001 (in order to become FP- Investigators). FIMP-
MCRN must, as a mandatory task, build up all the com-
petences required, facilitate co-operation, and avoid the
duplication of studies. Furthermore, FIMP-MCRN aims
to organize a higher standard of training, creating a Clini-
cal Research Master Course and an FIMP-National
School of Research and Investigations which has no otherNapoleone and Mele Italian Journal of Pediatrics 2010, 36:46
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object than to train all the FPI according to the principles
of paediatric clinical trials.
Creating specific competence means:1) creating a pae-
diatric "expertise" which will be necessary for better qual-
ity research. 2) implementing and wide-spreading the
FIMP-MCRN which already exists on a national scale.
This can happen thanks to two separate levels of training:
the first level with the training of a large number of FPI
(M.D. n.139/2001); the second level with the training of a
team of FPI (by means of Masters and Research Schools)
who will have a greater competence and will have to guar-
antee the quality of clinical studies [8-13].
For this purpose, training courses for FPI were run. The
main goals of the courses were: 1) to establish experi-
menter's responsibility, ethical regulations and informa-
tion quality to be given to patients. 2) to help
Paediatricians acquire all technical and cultural know-
how in order to guarantee an independent carrying out of
a research plan according to ethical principles, without
changing its professional profile. 3) to determine the
most adequate methods of developing a rigorous safety
examination activity and an appropriate use of medicines
in paediatrics. The main themes examined are: a) the
importance of clinical research and drug experimentation
in paediatrics; b) the distinctive feature of pharmacoki-
netics and pharmacodynamics in paediatric age groups,
the regulations, the terminology and methodology of
experimentation; c) a functional use of pharmacological
therapy in order to reveal the best risk/benefit balance; d)
a Good Clinical Practice, guidelines and ethical com-
ments about medicine experimentation in paediatrics; e)
the structure of a research project keeping in mind ethi-
cality, criticality and quality; f) the role and responsibili-
ties of the Ethics Committee, the relationships between
researchers-sponsors-monitors-CE, informed consent
and approval of minors, medical-legal and insurance
aspects, privacy, aspects of clinical epidemiology and
healthcare statistics; g) the evaluation and taking care of
unfavourable events during clinical experimentation of
medicines and with particular reference to Pharmacovigi-
lance on the territory; h) the opportunities and criticality
of family paediatricians' research and experimentation.
A Research School will be founded, which will also be a
pro-active observatory of analysable and improvable bio-
psychosocial phenomena. These will then help, in scien-
tific terms, Family Paediatricians to acquire the necessary
competence for "high quality research standards"
di r ect ed t o t he  sa f egua r d o f  vulne r a ble  peopl e  su c h as
paediatric age group subjects.
At the end of the training, FPI will be able to plan and
run a research protocol; they will also be able to apply all
the ethical regulations together with all the methodolo-
gies and strategies for a scientific autonomy in order to
improve their own competence and medical care stan-
dards. A category of FPI, who will be experts in running
clinical studies and with tested abilities, will be the core of
all of the scientific production when talking about territo-
rial paediatrics.
FIMP Quality Management System
The first step towards structural organisation was taken
when the AIFA, as an institution, awarded the recogni-
tion of Institute of FIMP Excellence in Research and
Investigations to a non-profit scientific or research asso-
ciation/company. The above mentioned institute is the
FIMP-MCRN. This Network has been acknowledged as a
National, transversal network by the EMA.
A clinical research project seeks the cooperation of a
large number of people with different types of compe-
tence and who must work according to precise method-
ological rules in order to assure high standards of quality.
Many other characters support family paediatrician clini-
cal studies (secretaries, administrative workers, accoun-
tants, experts in policy privacy, computer engineers, etc.)
in order to organise perfectly structured trials which
avoid family embarrassment and concern.
The FIMP has got a quality management system, a
Quality Control System (FPI- Monitor) that guarantees
the ICH-GCP, a Quality Assurance (FPI- Auditor) which
carries out some audits to check the QA as required by
the ICH regulations, a Legal and Insurance advise is given
for both forensic medicine and insurance aspects of trials
and for policy privacy, an Fimp in-house Steering Com-
mittee (a preliminary control before sending the research
projects to the National Ethical Committees), a Safety
Monitoring (control of possible ADRs in clinical trials).
The traceability, the transparency and the safety of data
are submitted to an computer engineering company
called VAM Srl which has an ISO 27001 Certification.
The role of the Quality Assurance (FPI-Auditor) there-
fore, is not "to produce" quality but to verify that all the
different aspects of the system are satisfactory. Audits are
carried out in accordance with the European Network of
GCP Auditors and other GCP Experts (ENGAGE).
FIMP has improved its own standards of operational
procedures (SOP), granting the highest levels of control
in transparency, safety and quality of data and of submit-
ted studies. Statistic analysis is carried out by both statis-
tic experts and FPI with expertise in healthcare statistics.
The Coordination Centre has the task to monitor the
Enrolling Centres, the observance of GCP regulations
and a surveillance task on the follow ups. Secretarial staff
arranges investigator's meetings, are a logistical connec-
tion and support with the enrolling centres and Ethics
Committees.
Research Working Group (RWG) and Steering 
Committee
Under the supervision of the head of FIMP-MCRN and
with the collaboration of Regional Referents a ResearchNapoleone and Mele Italian Journal of Pediatrics 2010, 36:46
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Working Group (RWG) has been formed with the follow-
ing aims: 1) establish territorial Inventories of Paediatric
Needs which can help to understand research priorities;
2) monitor off-label medicines which disadvantage the
paediatric population; 3) monitor medicines which are
close to patent expiry; 4) monitor orphan drugs (rare dis-
eases); 5) to urge towards a iatrogenic pathology culture
which creates a more careful control of Paediatric medi-
cines' risk/benefit ratio; 6) create an Network of pharma-
covigilance which can work in synergy with the National
Network of Pharmacovigilance;7) establish territorial
surveys (e.g. Medicine Registers).
This Group will be called to draw up research projects
especially for independent research (AIFA notices for a
competition, Ministerial notices for a competition, etc).
The Paediatric Working Group is coordinated by a
Steering Committee inside the FIMP, formed by family
paediatricians who have the best competence and experi-
ence. The Steering Committee, with the responsibility
and supervision of the Head of FIMP-MCRN, will have
the task of proposing research projects, regular review-
ing, organising training courses, epidemiological investi-
gating, attending to international conferences, magazine
publishing with IF and everything which has to do with
science and that will be considered useful for family pae-
diatricians' clinical research. Moreover, the Steering
Committee will control, verify and implement all the sci-
entific activities proposed and/or suggested by each
member of the RWG.
Finally, the Steering Committee will have the task to
verify the methodological quality of all the research proj-
ects which will then be evaluated by Ethics Committees.
Clinical studies experience
Since 2003, the year FIMP-MCRN was founded, Family
Paediatricians have participated to various clinical stud-
ies and research projects in collaboration with the most
important national Universities and/or Research Insti-
tutes [14-26]. This has allowed them to acquire experi-
ence and rigorous methodology in clinical paediatrics
research. Despite the fact that in the opening phases,
Family Paediatrician involvement in clinical trials was
quite poor throughout the Italian territory, from 2007 a
national organisation has created the characteristics for a
fully independent scientific running of clinical trials [27].
This involved the best Family Paediatricians and
Regional Referents together with so many other profes-
sionals, each with their own competence (lawyers, statis-
tic experts, secretaries, computer engineers, etc.) which
has assured quality, methodology and a correct running
of clinical studies.
The objectives of the FIMP - MCRN are to develop
expertise in multi-centre clinical drug trials in the paedi-
atric population. The network is coordinated by the Head
who is responsible for organizing and performing certi-
fied training programs and network meetings, feasibility
assessments, communication with companies, Ethics
Committees, and regulatory authorities (AIFA-Italian
Agency of Drug Evaluations).
Harmonized Standard Operating Procedures (SOP), a
clinical trial database, standardized essential study docu-
ments (e.g. patient and parent information, informed
consent, documents for assent), and a curriculum for
training courses for FPI, have all been established.
A great part of completed trials since 2003 are aca-
demia based studies. From 2009 there are four on going
clinical studies. The majority address drugs in the follow-
ing areas: gastroenterology, allergology, dermathology,
neurology, infectious diseases and disease prevention.
The FIMP - MCRN also share competence and experi-
ence with other European networks.
Epidemiological post-marketing studies
When the drug is used in clinical practice in large unse-
lected populations, epidemiological post-marketing stud-
ies are useful as they find their major confirmation in
recalling all the events that occur during monitoring,
with estimates of incidence of ADRs that can not be
obtained by spontaneous reports [3,9,10]. In these studies
a significant role can be played by the FPI with the partic-
ipation to active pharmacovigilance projects:
1) Family Paediatricians -FIMP- Antibiotics Tolerability 
Profile Study (FIMP-ATPS)
The FIMP wanted to promote a study of the assessment
of tolerability in the days of administration of Cefaclor
compared with amoxicillin-clavulanate [27].
The primary objective of the Study (FIMP-ATPS) was
to assess in patients with pharyngotonsillitis (FT) and
rhinosinusitis (RS) the tolerability profile of Cefaclor and
Amoxicillin + Clavulanic acid after the days of adminis-
tration. For the group of patients assigned to treatment
arm the regime of Cefaclor dosage was 50 mg/kg/day for
5 days for the FT and for 14 days for the RS, for the one
with amoxicillin + Ac. Clavulanic it was 50 mg/kg/day for
10 days for the FT and for 14 days for R.S. A total of 537
patients of both sexes, between 4 and 14 years of age were
enrolled, including 435 diagnosed with pharyngotonsilli-
tis (FT) and 102 cases with a rhinosinusitis (RS) diagno-
sis.
No major reactions were reported. Reported minor
adverse reactions were: nausea, vomiting, diarrhea,
abdominal pain, rashes, itching, loss of appetite, bloating,
borborygmi, constipation, change in the hive, irritability.
In the Cefaclor-group (257 children): 26 children
(10,1%) have reported only one minor reaction, 41 (16%)
more than one minor reaction and 190 (73,9%) did not
report any reactions.Napoleone and Mele Italian Journal of Pediatrics 2010, 36:46
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In the Amoxicillin-Clavulanic Acid group (262 chil-
dren), 37 children (14,1%) have reported only one minor
reaction and 71 (27,1%) more than one minor reaction,
while 154 (58,8%) did not report any reactions. Minor
adverse reactions, mainly gastrointestinal plead for a bet-
ter Cefaclor tolerability (p < 0.001) when comparing
Cefaclor to Amoxi-clavulanate.
2) (H1N1) Flu virus Surveillance System - INFLUNET Family 
Paediatricians Sentinel in collaboration with ISS (National 
Institute of Health)
Starting from 19 October 2009, the H1N1 Flu Virus sur-
veillance system is based on Influnet and collects all the
cases reported of those clients of the network of sentinel
physicians, as well as data on viruses circulating the net-
work of accredited laboratories.
In epiweek 45 [28] the incidence of H1N1, as detected
through sentinel FP surveillance, was 28.19 per 1,000 in
the 0-4 yrs. age group and 40.78 per 1,000 in the 5-14yr
age group After having peeked the H1N1 epicurve has
declined and then stabilized.
1172 reports of suspected adverse reactions after the
administration of pandemic vaccine Focetria, out of a
total of 898.562 doses were included in the National
Pharmacovigilance Network.
About 15% reports are of children up to 11 years of age
(7 severe) and 4% relate to teenagers and all other older
age groups. Most frequently reported reactions are head-
ache (the most frequently reported reaction of the ner-
vous system), fever and joint pain. At the moment of
administration various types of local reactions such as
pain, swelling, erythema were also reported [29].
3) Disease Register -FIMP DUMBO Otitis Study
The study is an epidemiological survey on observed acute
otitis media in a Italian pediatric population. The main
objective of the project is to create a disease register and
to evaluate the incidence of AOM in all children aged
between 0 and 59 months in relation to their clinical
severity or recurrence. The clinical diagnosis of AOM,
according to the recommendations of the AAP, will be
supported by a Pneumatic Otoscope. This study is on-
going
International activity of FIMP-MCRN
The European Paediatric Regulation have the aim to
increase the number of suitably studied medicines
adapted for a potential use in children of different age
groups and to go towards research on an international
basis by planning to establish, thanks to EMA's help, a
European Network of researchers and institutes with spe-
cific competence in running pharmacological experi-
ments in the paediatric field [4,5].
To achieve these objectives the EMA is tasked with
developing a European Network of Paediatric Research at
the EMA (ENPREMA) of existing national and European
networks and centres with specific expertise in research
and clinical trials relating to paediatric medicines with
the scientific support of the Pediatric Committee. The
ENPREMA objectives will be: a) to harmonize clinical
trial procedures (SOP's, documents, data management,
monitoring, training curricula, etc.) - at European level;
b) to define strategies in order to solve major challenges
of pediatric clinical trials (insurance, divergent Ethic
Committee positions, lack of pediatric expertise, etc.) - at
European level; c) to ensure effective coordination and
communication between individual networks, investiga-
tors and pediatric clinical trial centres; d) to stimulate and
facilitate the development and integration of new
national networks and trial centres; e) to link together
existing networks; f) to provide expertise and access to
infrastructure for industry to conduct studies in children;
g) to define consistent and transparent quality standards;
h) to define strategies for resolving major challenges; i) to
communicate with external stakeholders.
On the 16th of February 2009 the EMA organised a
one-day workshop to discuss and initiate the develop-
ment of this ENPREMA [6]. The result of this workshop
was the proposal to create a Coordinating Group and to
point out recognition criteria and quality standard to be
fulfilled by networks which intend to become members of
the future ENPREMA.
The objectives Coordinating Group will be: 1) to con-
tribute to the short and long-term strategy; 2) to discuss
and solve operational and scientific issues; 3) to discuss
and confirm scientific quality standards; 4) to act as a
forum for communication; 5) to contribute to the short
and long-term strategy of the network; 6) to report to the
Pediatric Committee (PDCO).
Two working groups were formed: the first with the
task to elaborate structure, composition and duties of the
Coordinating group, the second with the task to elaborate
and find agreement consensus on the recognition criteria
and quality standard.
On the 16th of March 2010 the EMA organised a sec-
ond one-day workshop to discuss the right composition
of the Coordinating Group and the publication of fina-
lised recognition criteria for self-assessment.
Even Family Paediatrics, thanks to its Network, recogn-
ised at a European level (can be found in the list of Euro-
pean Networks), is ready to become part of the European
Network by helping to create the ENPREMA.
Family Paediatrics is part of the Working Group of
Medicines for Children of the EAP (European Academy
of Paediatrics) and this will grant new medicine researchNapoleone and Mele Italian Journal of Pediatrics 2010, 36:46
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opportunities in the paediatric field and will guarantee an
enduring of experience and competence.
In 2010 the FIMP- MCRN has become a member of the
ENCePP (The European Network of Centres for Pharma-
coepidemiology and Pharmacovigilance).
The FIMP-MCRN participated in international confer-
ences last year (Excellences in Paediatrics -Florence) pre-
senting the results of epidemiological pharmacovigilance
surveys [30] and will participate this year for other Inter-
national Congress (IPA- Johannesburg and EAPS-Copen-
hagen).
Future prospects
Paediatric clinical trials are necessary to make progress in
children's care. The EUPR wants to link together and
coordinate existing networks, establish a platform for
communication and exchange of information between
European networks and share the skills and expertise in
order to cut to shape and influence future development in
paediatric research. Networking is necessary to build up
the competence, to make co-operation easier and to avoid
duplication of studies.
The main target of Family Paediatricians should be to
regain possession of the research aspect of the profession
through the fundamentals of science and the production
and publishing of paper work about primary care in order
to guarantee greater knowledge and better decision-mak-
ing.
The net must be aware and ready for specific training
s o  t h a t  i t  c a n  a n s w e r  w i t h  a u t h o r i t y  f o r  i n d e p e n d e n t
research. Quality and ethicality of research are becoming
important end-points of territorial Paediatrics, opportu-
nities and challenges of Family Paediatricians during their
education and during the sponsoring of health and pre-
vention in the paediatric age groups.
Family Paediatricians are convinced that the path they
are following is the right one and this is due to the fact
that they have great scientific enthusiasm even if they
understand that a long distance still has to be covered and
there is so much to do in order to make territorial paedi-
atric research possible and useful.
One of the chances in the future is to become part of
the ENPREMA which carry out pharmacological experi-
ments in the paediatric field and another one is to take
part in pharmacovigilance research coordinated by
ENCePP.
These possibilities could grant new paediatric medicine
research opportunities for Italian family paediatricians
and could guarantee further exchange of experience and
competence, being an important wedge in the cultural
mosaic of paediatric research.
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